Company profile
Delcath Systems
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of metastatic liver cancer.
- Industry
- Pharmaceutical Manufacturing
- Employees
- 150
- Headquarters
- New York, NY
- Founded
- 1987
- LinkedIn followers
- 8,799
- Office locations
- 3
Delcath Systems company summary
Delcath Systems is a company in the Pharmaceutical Manufacturing industry, headquartered in New York, NY, founded in 1987. On LinkedIn the company has around 150 employees and 8,799 followers. The company lists 3 office locations. Its listed specialties include Oncology, Research & Development, Liver Cancers, Ocular Melanoma, Intrahepatic cholangiocarcinoma.
What technology does Delcath Systems use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Delcath Systems
Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.
Specialties
Where is Delcath Systems located?
Delcath Systems lists 3 office locations.
Compare companies similar to Delcath Systems
More companies in Pharmaceutical Manufacturing.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Delcath Systems delcath.com | Pharmaceutical Manufacturing | 150 | 1987 | New York, NY |
 Anacor Pharmaceuticals pfizer.com | Pharmaceutical Manufacturing | 108,102 | - | New York, New York |
 Sanofi sanofi.com | Pharmaceutical Manufacturing | 93,352 | - | Paris, France, FR |
 GSK gsk.com | Pharmaceutical Manufacturing | 92,179 | - | London, England |
 Novartis España novartis.com | Pharmaceutical Manufacturing | 85,373 | - | Basel, Baselstadt |
 AstraZeneca astrazeneca.com | Pharmaceutical Manufacturing | 80,667 | - | Cambridge, Cambridgeshire, GB |
 Eli Lilly and Company lilly.com | Pharmaceutical Manufacturing | 57,202 | - | Indianapolis, Indiana |
 Merck merck.us | Pharmaceutical Manufacturing | 44,794 | - | Rahway, New Jersey |
 SUN PHARMA sunpharma.com | Pharmaceutical Manufacturing | 47,764 | 1983 | Mumbai, Maharastra |
 Boehringer Ingelheim boehringer-ingelheim.com | Pharmaceutical Manufacturing | 47,150 | - | Ingelheim am Rhein, Rhineland-Palatinate |
 Cipla cipla.com | Pharmaceutical Manufacturing | 51,911 | - | Mumbai, Maharashtra |
Frequently asked questions about Delcath Systems
What does Delcath Systems do?
Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.
How many employees does Delcath Systems have?
Delcath Systems has around 150 employees on LinkedIn.
Where is Delcath Systems headquartered?
Delcath Systems is headquartered in New York, NY.
Where does Delcath Systems have offices?
Delcath Systems lists 3 office locations, including New York, NY, US; Galway, IE, IE; Queensbury, NY, US.
When was Delcath Systems founded?
Delcath Systems was founded in 1987.
Build a lead list from companies like Delcath Systems
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.